1. Home
  2. PRHI vs COCP Comparison

PRHI vs COCP Comparison

Compare PRHI & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Presurance Holdings Inc.

PRHI

Presurance Holdings Inc.

N/A

Current Price

$5.34

Market Cap

14.2M

Sector

Finance

ML Signal

N/A

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$0.94

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRHI
COCP
Founded
2009
2006
Country
United States
United States
Employees
9
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
14.1M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
PRHI
COCP
Price
$5.34
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
8.7K
56.5K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
N/A
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.86
52 Week High
$6.40
$2.19

Technical Indicators

Market Signals
Indicator
PRHI
COCP
Relative Strength Index (RSI) 59.58 36.60
Support Level $0.60 $0.91
Resistance Level $5.34 $1.09
Average True Range (ATR) 0.32 0.03
MACD -0.10 -0.00
Stochastic Oscillator 40.71 0.00

Price Performance

Historical Comparison
PRHI
COCP

About PRHI Presurance Holdings Inc.

Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: